한글목차

BIIB-122는 루신이 풍부한 반복 키나아제2(LRRK2)에 대한 선택적 중추신경 투과성 저분자 억제제이며, 파킨슨병의 기초 생물학에 영향을 미치고 진행을 늦추는 것을 목표로 하는 새로운 표적이 될 수 있습니다. LRRK2 활성은 파킨슨병에 관여하는 근본적인 생물학적 경로를 표적으로 하는 새로운 접근법이며, LRRK2 활성은 파킨슨병에서 증가하여 리소좀 기능을 부정적으로 조절하며, LRRK2의 저해는 리소좀 기능을 회복하고 단백질 처리를 정상화합니다.

현재 LRRK2 유전자 변이가 있는 파킨슨병 환자를 대상으로 한 임상 III상 LIGHTHOUSE 시험과 임상 IIb상 LUMA 시험이 진행 중입니다.

앞으로 몇 년동안 파킨슨병 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 증가로 인해 변화할 것입니다. 각 회사는 병을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, BIIB-122의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 다른 파킨슨병 치료제들도 BIIB-122와 치열한 시장 경쟁을 벌일 것으로 예상되며, 조만간 후발 신약이 출시될 경우 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 파킨슨병 치료제 BIIB-122 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 파킨슨병에서의 BIIB-122개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 BIIB-122 시장 평가

• 파킨슨병용 BIIB-122 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 파킨슨병 치료제 BIIB-122 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"BIIB-122 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about BIIB-122 for Parkinson's disease in the seven major markets. A detailed picture of the BIIB-122 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the BIIB-122 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BIIB-122 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

BIIB-122 is a selective, central nervous system-penetrant small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), a potential novel target intended to impact the underlying biology and slow the progression of Parkinson's disease. Inhibition of LRRK2 is a novel approach designed to target an underlying biological pathway implicated in Parkinson's disease. LRRK2 activity is increased in Parkinson's disease and negatively regulates lysosomal function; LRRK2 inhibition rescues lysosomal function and normalizes protein processing.

Presently the drug is being evaluated in a Phase III LIGHTHOUSE trial and a Phase IIb LUMA trial in individuals with Parkinson's disease with LRRK2 pathogenic variants.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the BIIB-122 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on BIIB-122 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the BIIB-122 research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around BIIB-122.
• The report contains forecasted sales of BIIB-122 for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for BIIB-122 in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BIIB-122 Analytical Perspective by DelveInsight

• In-depth BIIB-122 Market Assessment

This report provides a detailed market assessment of BIIB-122 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

• BIIB-122 Clinical Assessment

The report provides the clinical trials information of BIIB-122 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BIIB-122 dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to BIIB-122 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BIIB-122 in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of BIIB-122 from 2028 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BIIB-122 in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of BIIB-122?
• What is the clinical trial status of the study related to BIIB-122 in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BIIB-122 development?
• What are the key designations that have been granted to BIIB-122 for Parkinson's disease?
• What is the forecasted market scenario of BIIB-122 for Parkinson's disease?
• What are the forecasted sales of BIIB-122 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to BIIB-122 for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. BIIB-122 Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. BIIB-122 Market Assessment

• 5.1. Market Outlook of BIIB-122 in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of BIIB-122 in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of BIIB-122 in the United States for Parkinson's disease
  • 5.3.2. Market Size of BIIB-122 in Germany for Parkinson's disease
  • 5.3.3. Market Size of BIIB-122 in France for Parkinson's disease
  • 5.3.4. Market Size of BIIB-122 in Italy for Parkinson's disease
  • 5.3.5. Market Size of BIIB-122 in Spain for Parkinson's disease
  • 5.3.6. Market Size of BIIB-122 in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of BIIB-122 in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options